These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 22370309

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 3. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S.
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
    [Abstract] [Full Text] [Related]

  • 10. [Combination therapy for osteoporosis].
    Kishimoto H.
    Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
    [Abstract] [Full Text] [Related]

  • 11. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
    Cosman F.
    Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
    [Abstract] [Full Text] [Related]

  • 12. Oral antiresorptive therapy.
    Pande I, Hosking DJ.
    Curr Rheumatol Rep; 2005 Mar; 7(1):71-7. PubMed ID: 15760584
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface.
    Li YF, Li XD, Bao CY, Chen QM, Zhang H, Hu J.
    Osteoporos Int; 2013 Mar; 24(3):1063-71. PubMed ID: 23296744
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, effectiveness and side effects of medications used to prevent fractures.
    Reid IR.
    J Intern Med; 2015 Jun; 277(6):690-706. PubMed ID: 25495429
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M, Marumo K.
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of dosing frequency of teriparatide (PTH 1-34) on bone formation in rats: comparison of bone metabolism marker levels.
    Watanabe A, Tsurui K, Yoneyama S, Iwata H, Anzai T, Jerome C, Nakae D.
    J Toxicol Sci; 2018 Mar; 43(7):435-442. PubMed ID: 29973475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.